The Trump administration has begun withholding federal funds from hospitals and providers that offer gender-affirming medical care to minors, issuing warnings that threaten financial support for such services nationwide.
The policy, enforced through the Department of Health and Human Services as of 18 December 2025, targets treatments including puberty blockers, hormone therapy, and surgeries for those under 18. It applies pressure even in states with protective laws.
An HHS official justified the move, stating: “Federal dollars should not support experimental treatments on children.” The administration views many interventions as insufficiently proven and potentially harmful long-term.
Medical organisations strongly opposed the action. The president of the American Academy of Pediatrics said: “This politicises evidence-based care and harms vulnerable youth.” They cited studies showing benefits for mental health and reduced suicide risk.
Parents of transgender children expressed alarm. One advocate parent shared: “My child’s access to lifesaving treatment is now at risk.” Families fear disrupted care and increased distress.
The measure reverses guidance from previous years and escalates debates over youth transition. Several states ban or restrict such care, while others mandate coverage.
Providers face difficult choices between complying to retain funding or continuing services and risking penalties. Major hospital systems have received letters outlining compliance expectations.
Critics argue the policy constitutes federal overreach into medical practice, overriding physician judgment and family decisions. Supporters maintain it protects minors from decisions they may regret.
Legal challenges are anticipated from states, providers, and advocacy groups alleging discrimination and violation of healthcare laws. Similar past restrictions faced court blocks.
The development intensifies cultural and political divisions over transgender rights. Youth mental health organisations warn of broader harms from reduced access.
Written by Were Kelly
Sources: Reuters, Law360, The New York Times.
